ERBB2 and cancer: Besides, Thakur et al. [123] employed anti-CD19 CART armed with anti-CD3 (OKT3) × anti-HER2 bispecific antibodies (HER2Bi) or anti-CD3 (OKT3) × anti-EGFR bispecific antibodies (EGFRBi) to address the cytotoxicity against HER2 or EGFR positive cancer cell lines.